FDA's 1-Day Inspection Pilot Changes Inspection Readiness

FDA said in April 2026 that it had already completed about 46 one-day inspectional assessments, and Commissioner Marty Makary used the FDLI Annual Conference in Washington to make the point explicit: this is now part of the agency's oversight model. For quality teams that still define inspection readiness as surviving a five-day document pull, that number should land as a warning.

The scheduling change is only half the story. FDA also said facility selection is being supported by AI-assisted risk ranking built around product type, prior inspection outcomes, and operational characteristics. That means inspection readiness is no longer just about how you perform when investigators arrive. It also shapes how your site is categorized before they ever show up.

Small pharma manufacturers should not read the phrase "one-day assessment" as a softer visit. A compressed inspection can be harder on a weak quality system because it removes the recovery time that lets a site chase records, reconcile contradictions, and coach managers into cleaner answers. If an investigator walks in with a narrow risk hypothesis and one day to test it, the question is not whether your documents exist. The question is whether your system can surface the right records, the right owner, and the right rationale immediately.

That matters most in the areas FDA keeps treating as proof of control rather than proof of paperwork. Under 21 CFR 211.22(c), the quality unit is responsible for approving or rejecting procedures and records that affect drug quality. Under 21 CFR 211.192, unexplained discrepancies and failures must be thoroughly investigated. Those citations do not require a five-day inspection to expose a weak system. One open CAPA with no effectiveness evidence, one deviation investigation that stops at a symptom, or one batch-impact assessment that cannot explain its own scope can be enough to tell FDA what it needs to know.

ClinicalTrialVanguard's May 7 analysis framed the pilot around the sites that built readiness for traditional multi-day visits and may now be exposed on compressed review. The publication pointed directly to CAPA status and effectiveness, vendor oversight, and documentation readiness as pressure points. That logic travels cleanly into manufacturing quality. If your CAPA board looks healthy only because someone manually cleans up aging records before major visits, a one-day inspection is built to catch that. If your supplier controls live across disconnected spreadsheets, shared drives, and email chains, a one-day inspection is long enough to show that the oversight model is fragile.

Vendor oversight is especially exposed because it is one of the first places a risk-ranked inspection can go when FDA wants to test whether a site really understands its external dependencies. The firm may believe the supplier is qualified. The investigator will want to see how that conclusion was reached, how it was maintained, and what happened when the supplier changed a process, missed a specification, or triggered a complaint trend. For manufacturers operating under 21 CFR 211.84 and related component controls, the gap is often not the absence of an approved-supplier list. It is the absence of a defensible link between incoming controls, change evaluation, and actual quality-unit oversight.

Fierce Pharma's reporting reinforced a point too many teams will miss on first read: FDA is not replacing traditional inspections with a lighter model. The agency is expanding its range. That should change how quality leaders think about resource planning. The old readiness model assumed the inspection itself would reveal the scope over time. This pilot suggests FDA may increasingly arrive with the scope already narrowed, ranked, and prioritized by a machine-assisted screening process. When that happens, the first hour matters more than the fourth day used to.

There is also a leadership mistake buried inside the phrase "lower-risk site." If FDA sends a one-day team to a facility it currently considers lower risk, that is not a certificate of safety. It is a test of whether the classification holds up under targeted review. Sites that treat the pilot as a courtesy visit are likely to give away exactly what the model is trying to verify: whether the firm's calm self-description matches the condition of its records, investigations, and oversight decisions.

The practical exposure for smaller quality organizations is speed. Large manufacturers can sometimes hide weak system design behind specialist depth, document coordinators, and inspection war rooms. Small teams do not have that luxury. If the head of quality, the CAPA owner, and the supplier-quality lead are functionally the same two people, then inspection readiness has to be engineered into the daily system, not staged for the visit. A one-day assessment punishes performative readiness and rewards systems that stay organized when nobody had advance time to rehearse.

Marty Makary presented the pilot as a way to strengthen and expand oversight, not relax it. Read that phrase carefully. Stronger oversight with shorter visits only works if FDA believes it can extract a reliable control signal quickly. The agency's use of AI-assisted ranking suggests it believes the signal is already present in inspection history, product risk, and operational patterns before the visit begins. Quality teams should assume their own history is now helping define both inspection frequency and inspection style.

The immediate move is simple. This week, pull one open CAPA, one recent deviation with product-impact assessment, and one active supplier file. Then ask whether your team can put the full story on the table in 15 minutes, with dates, owners, approvals, and rationale that hold under challenge. If the answer depends on cleanup, interpretation, or a missing person being available, your site is not ready for FDA's one-day model yet.